APIMEDS PHARMACEUTICALS US I
APUSNYSE AMERICANTrading Snapshot
- Day Range
- $4.99 – $5.08
- 52-Week Range
- $1.51 – $59.70
- Volume
- $4.69B
- Avg Volume
- $5.95B
- Shares Outstanding
- 1.5M
- Next Earnings
- Nov 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $653,083
- Last Q Revenue
- $155,359
- P/E Ratio
- -0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-35.63
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +757.3%
Why Investors Own APUS
- ✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
APIMEDS PHARMACEUTICALS US I
APUS
StockOtter · stockotter.spaceAbout APIMEDS PHARMACEUTICALS US I
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media
MATAWAN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- MindWave Innovations Inc. ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has signed a 12-month software development an
Apimeds Pharmaceuticals Stock Skyrockets Thursday: What's Happening?
Apimeds Pharmaceuticals US Inc. (NYSE:APUS) shares are surging Thursday morning after its wholly owned subsidiary, MindWave Innovations Inc., announced a 12-month technology services agreement with Singapore-based AQUAE
MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits
MindWave will supply and operate the technology, while AQUAE leads the ALCI Credits methodology, brand and market development MindWave will supply and operate the technology, while AQUAE leads the ALCI Credits methodolog
IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.
AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN, a multifaceted financial news and publishing company serving private and public entities
NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange
MATAWAN, New Jersey / GEORGE TOWN, Cayman Islands, Aug. 03, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“MindWave In
MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October
MATAWAN, New Jersey, and GEORGE TOWN, Cayman Islands, July 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("MindWave